Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: Characterization and in vitro evaluations

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 3, 2010, Pages 320-335

  Doroud, Delaram ^a,b   Vatanara, AlirezaVatanara ^a   Zahedifard, Farnaz ^b   Gholami, Elham ^b   Vahabpour, Rouhollah ^b   Najafabadi, Abdolhossein Rouholamini ^a   Rafati, Sima ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL; CYSTEINE PROTEINASE; DEOXYRIBONUCLEASE I; DNA VACCINE; LEISHMANIA VACCINE; PLASMID DNA; POLYSORBATE 80; SOLID LIPID NANOPARTICLE;

ARTICLE; CELL STRAIN COS7; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CPA GENE; CPB CTE GENE; CPB GENE; CYTOTOXICITY; DNA IMMUNIZATION; DRUG FORMULATION; DRUG STABILITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE; IMMUNOGENICITY; IN VITRO GENE TRANSFER; IN VITRO STUDY; LEISHMANIASIS; PARTICLE SIZE; SURFACE PROPERTY; ZETA POTENTIAL;

EID: 78650333038     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3r30t     Document Type: Article

References (24)

1. WHO. Leishmaniasis Home Page. World Health Organization website, 8-21-2006, http://www.who.int/leishmaniasis/burden/en/.
2. Kedzierski, L., Sakthianandeswaren, A., Curtis, JM., Andrews, PC., Junk, PC. and Kedzierska, K., Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem., 16:599-614. 2009.
3. Verthelyi, D. and Klinman, DM., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol, 109:64-71, 2003.
4. Reed, S. G., Bertholet, S., Coler, R. N. and Friede, M., New horizons in adjuvants for vaccine development. Trends Immunol, 30: 23-32, 2009.
5. Palatnik-de-Sousa, C. B., Vaccines for leishmaniasis in the fore coming 25 years. Vaccine, 26: 1709-1724, 2008.
6. Rafati, S., Fasel, N. and Masina, S., Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine. Curr Genomics, 4: 253-261. 2003.
7. Rafati, S., Salmanian, AH., Taheri, T., Vafa, M. And Fasel, N., A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19: 3369-75. 2001.
8. Rafati, S., Nakhaee, A., Taheri, T., Taslimi, Y., Darabi, H., Eravani, D., Sanos, S., Kaye, P., Taghikhani, M., Jamshidi, S. and Rad, MA., Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine. 23: 3716-25. 2005.
9. Rafati, S., Zahedifard, F., Azari, M.K, Taslimi, Y. and Taheri, T., Leishmania infantum: prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp Parasitol. 118: 393- 401, 2008.
10. Wilson, K.D., de Jong, SD. and Tam, YK., Lipidbased delivery of CpG oligonucleotides enhances immunotherapeutic efficacy. Adv Drug Del Rev, 61: 233-242, 2009.
11. Muller, R.H., Mader, K. and Gohla, S., Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50: 161-177, 2000.
12. Muller, R.H., Ruhl, D., Runge, S., Schulze-Forster, K. and Mehnert, W., Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 14: 458-462. 1997.
13. Joshi, M.D. and Müller, R.H., Lipid nanoparticles for parenteral delivery of actives. Eur J Phar Biopharm, 71:161-172, 2009.
14. Tabatt, K., Sameti, M., Olbrich, C., Müller, R.H. and Lehr, C.M., Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm, 57: 155-162, 2004.
15. del Pozo-Rodríguez, A., Delgado, D., Solinís, M.A., Gascón, A.R. and Pedraz, J.L., Solid lipid nanoparticles: Formulation factors affecting cell transfection capacity. Int J Pharm, 339: 261-268, 2007.
16. del Pozo-Rodríguez, A., Delgado, D., Solinís, M. Á., Pedraz, J. L., Echevarría, E., Rodríguez, J. M. and Gascón, A. R., Solid lipid nanoparticles as potential tools for gene therapy: In vivo protein expression after intravenous administration. Int J Pharm., In Press, Corrected Proof, Available online 14 October 2009.
17. Von Stebut, E. and Udey, M.C., Requirements for Th1-dependent immunity against infection with L. major. Microbs and Infection, 6:1102-1109, 2004.
18. Olbrich, C., Bakowsky, U., Lehr, C.M., Müller, R.H. and Kneuer, C., Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Rel, 77: 345-355. 2001.
19. Heiati, H., Tawashi, R. and Phillips, N.C., Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization. J Microencapsul, 15: 173-184, 1998.
20. Rudolph, C., Schillinger, U., Ortiz, A. Tabatt, K. Plank, C. and Muller, R.H., Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo, Pharm Res, 21: 1662-1669, 2004.
21. Gebhart, C. L. and Kabanov, A.V., Evaluation of polyplexes as gene transfer agents. J Control Rel, 73: 401-416, 2001.
22. Feng, M., Lee, D. and Li, P., Intracellular uptake and release of poly (ethyleneimine)-co-poly (methyl methacrylate) nanoparticle/pDNA complexes for gene delivery. Int J Pharm., 311: 209-214, 2006.
23. Vighi, E., Ruozi, B., Montanari, M., Battini, R. and Leo, E., Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: characterization and ability to bind the pEGFP-plasmid. Eur J Pharm Biopharm., 67(2):320-8, 2007.
24. Vighi, E., Ruozi, B., Montanari, M., Battini, R. and Leo, E., pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. Int J Pharm, 389: 254-261, 2010.